Quinn T. Ostrom, Gino Cioffi, Haley Gittleman et al.:CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016. In: Neuro-Oncology. Band21, Supplement_5, 1.November 2019, ISSN1522-8517, S.v1–v100, doi:10.1093/neuonc/noz150, PMID 31675094, PMC6823730(freier Volltext) – (englisch).
David N Louis, Arie Perry, Pieter Wesseling, Daniel J Brat, Ian A Cree:The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. In: Neuro-Oncology. Band23, Nr.8, 2.August 2021, ISSN1522-8517, S.1231–1251, doi:10.1093/neuonc/noab106, PMID 34185076, PMC8328013(freier Volltext) – (oup.com[abgerufen am 6.Oktober 2021]).
Julie J Miller, L Nicolas Gonzalez Castro, Samuel McBrayer et al.:Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. In: Neuro-Oncology. Band25, Nr.1, 5.Januar 2023, ISSN1522-8517, S.4–25, doi:10.1093/neuonc/noac207, PMID 36239925, PMC9825337(freier Volltext).
Serena Ammendola, Giuseppe Broggi, Valeria Barresi:IDH-mutant diffuse gliomas: Tips and tricks in the era of genomic tumor classification. In: Histology and Histopathology. Band38, Nr.07, 2023, ISSN0213-3911, S.739–753, doi:10.14670/HH-18-582.
Rouzbeh Banan, Damian Stichel, Anja Bleck et al.:Infratentorial IDH-mutant astrocytoma is a distinct subtype. In: Acta Neuropathologica. Band140, Nr.4, Oktober 2020, ISSN0001-6322, S.569–581, doi:10.1007/s00401-020-02194-y.
Abigail K. Suwala, Damian Stichel, Daniel Schrimpf et al.:Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. In: Acta Neuropathologica. Band141, Nr.1, Januar 2021, ISSN0001-6322, S.85–100, doi:10.1007/s00401-020-02243-6, PMID 33216206, PMC7785563(freier Volltext).
Julie J Miller, L Nicolas Gonzalez Castro, Samuel McBrayer et al.:Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. In: Neuro-Oncology. Band25, Nr.1, 5.Januar 2023, ISSN1522-8517, S.4–25, doi:10.1093/neuonc/noac207, PMID 36239925, PMC9825337(freier Volltext).
Serena Ammendola, Giuseppe Broggi, Valeria Barresi:IDH-mutant diffuse gliomas: Tips and tricks in the era of genomic tumor classification. In: Histology and Histopathology. Band38, Nr.07, 2023, ISSN0213-3911, S.739–753, doi:10.14670/HH-18-582.
Abigail K. Suwala, Marius Felix, Dennis Friedel et al.:Oligosarcomas, IDH-mutant are distinct and aggressive. In: Acta Neuropathologica. Band143, Nr.2, Februar 2022, ISSN0001-6322, S.263–281, doi:10.1007/s00401-021-02395-z, PMID 34967922, PMC8742817(freier Volltext).
Sanjay Shete, Fay J Hosking, Lindsay B Robertson et al.:Genome-wide association study identifies five susceptibility loci for glioma. In: Nature Genetics. Band41, Nr.8, August 2009, ISSN1061-4036, S.899–904, doi:10.1038/ng.407, PMID 19578367, PMC4501476(freier Volltext).
Margaret Wrensch, Robert B Jenkins, Jeffrey S Chang et al.:Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. In: Nature Genetics. Band41, Nr.8, August 2009, ISSN1061-4036, S.905–908, doi:10.1038/ng.408, PMID 19578366, PMC2923561(freier Volltext).
Godehard Koch: Bildmorphologische Parameter präoperativer MR-Tomogramme und Überlebenszeit von Patienten mit malignen Gliomen. Dissertation. FU Berlin, 1.Einleitung (PDF) statische URL
Quinn T. Ostrom, Gino Cioffi, Haley Gittleman et al.:CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016. In: Neuro-Oncology. Band21, Supplement_5, 1.November 2019, ISSN1522-8517, S.v1–v100, doi:10.1093/neuonc/noz150, PMID 31675094, PMC6823730(freier Volltext) – (englisch).
David N Louis, Arie Perry, Pieter Wesseling, Daniel J Brat, Ian A Cree:The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. In: Neuro-Oncology. Band23, Nr.8, 2.August 2021, ISSN1522-8517, S.1231–1251, doi:10.1093/neuonc/noab106, PMID 34185076, PMC8328013(freier Volltext) – (oup.com[abgerufen am 6.Oktober 2021]).
Julie J Miller, L Nicolas Gonzalez Castro, Samuel McBrayer et al.:Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. In: Neuro-Oncology. Band25, Nr.1, 5.Januar 2023, ISSN1522-8517, S.4–25, doi:10.1093/neuonc/noac207, PMID 36239925, PMC9825337(freier Volltext).
Abigail K. Suwala, Damian Stichel, Daniel Schrimpf et al.:Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. In: Acta Neuropathologica. Band141, Nr.1, Januar 2021, ISSN0001-6322, S.85–100, doi:10.1007/s00401-020-02243-6, PMID 33216206, PMC7785563(freier Volltext).
Julie J Miller, L Nicolas Gonzalez Castro, Samuel McBrayer et al.:Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. In: Neuro-Oncology. Band25, Nr.1, 5.Januar 2023, ISSN1522-8517, S.4–25, doi:10.1093/neuonc/noac207, PMID 36239925, PMC9825337(freier Volltext).
Abigail K. Suwala, Marius Felix, Dennis Friedel et al.:Oligosarcomas, IDH-mutant are distinct and aggressive. In: Acta Neuropathologica. Band143, Nr.2, Februar 2022, ISSN0001-6322, S.263–281, doi:10.1007/s00401-021-02395-z, PMID 34967922, PMC8742817(freier Volltext).
Sanjay Shete, Fay J Hosking, Lindsay B Robertson et al.:Genome-wide association study identifies five susceptibility loci for glioma. In: Nature Genetics. Band41, Nr.8, August 2009, ISSN1061-4036, S.899–904, doi:10.1038/ng.407, PMID 19578367, PMC4501476(freier Volltext).
Margaret Wrensch, Robert B Jenkins, Jeffrey S Chang et al.:Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. In: Nature Genetics. Band41, Nr.8, August 2009, ISSN1061-4036, S.905–908, doi:10.1038/ng.408, PMID 19578366, PMC2923561(freier Volltext).
David N Louis, Arie Perry, Pieter Wesseling, Daniel J Brat, Ian A Cree:The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. In: Neuro-Oncology. Band23, Nr.8, 2.August 2021, ISSN1522-8517, S.1231–1251, doi:10.1093/neuonc/noab106, PMID 34185076, PMC8328013(freier Volltext) – (oup.com[abgerufen am 6.Oktober 2021]).
Quinn T. Ostrom, Gino Cioffi, Haley Gittleman et al.:CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016. In: Neuro-Oncology. Band21, Supplement_5, 1.November 2019, ISSN1522-8517, S.v1–v100, doi:10.1093/neuonc/noz150, PMID 31675094, PMC6823730(freier Volltext) – (englisch).
David N Louis, Arie Perry, Pieter Wesseling, Daniel J Brat, Ian A Cree:The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. In: Neuro-Oncology. Band23, Nr.8, 2.August 2021, ISSN1522-8517, S.1231–1251, doi:10.1093/neuonc/noab106, PMID 34185076, PMC8328013(freier Volltext) – (oup.com[abgerufen am 6.Oktober 2021]).
Julie J Miller, L Nicolas Gonzalez Castro, Samuel McBrayer et al.:Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. In: Neuro-Oncology. Band25, Nr.1, 5.Januar 2023, ISSN1522-8517, S.4–25, doi:10.1093/neuonc/noac207, PMID 36239925, PMC9825337(freier Volltext).
Serena Ammendola, Giuseppe Broggi, Valeria Barresi:IDH-mutant diffuse gliomas: Tips and tricks in the era of genomic tumor classification. In: Histology and Histopathology. Band38, Nr.07, 2023, ISSN0213-3911, S.739–753, doi:10.14670/HH-18-582.
Rouzbeh Banan, Damian Stichel, Anja Bleck et al.:Infratentorial IDH-mutant astrocytoma is a distinct subtype. In: Acta Neuropathologica. Band140, Nr.4, Oktober 2020, ISSN0001-6322, S.569–581, doi:10.1007/s00401-020-02194-y.
Abigail K. Suwala, Damian Stichel, Daniel Schrimpf et al.:Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. In: Acta Neuropathologica. Band141, Nr.1, Januar 2021, ISSN0001-6322, S.85–100, doi:10.1007/s00401-020-02243-6, PMID 33216206, PMC7785563(freier Volltext).
Julie J Miller, L Nicolas Gonzalez Castro, Samuel McBrayer et al.:Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. In: Neuro-Oncology. Band25, Nr.1, 5.Januar 2023, ISSN1522-8517, S.4–25, doi:10.1093/neuonc/noac207, PMID 36239925, PMC9825337(freier Volltext).
Serena Ammendola, Giuseppe Broggi, Valeria Barresi:IDH-mutant diffuse gliomas: Tips and tricks in the era of genomic tumor classification. In: Histology and Histopathology. Band38, Nr.07, 2023, ISSN0213-3911, S.739–753, doi:10.14670/HH-18-582.
Abigail K. Suwala, Marius Felix, Dennis Friedel et al.:Oligosarcomas, IDH-mutant are distinct and aggressive. In: Acta Neuropathologica. Band143, Nr.2, Februar 2022, ISSN0001-6322, S.263–281, doi:10.1007/s00401-021-02395-z, PMID 34967922, PMC8742817(freier Volltext).
Sanjay Shete, Fay J Hosking, Lindsay B Robertson et al.:Genome-wide association study identifies five susceptibility loci for glioma. In: Nature Genetics. Band41, Nr.8, August 2009, ISSN1061-4036, S.899–904, doi:10.1038/ng.407, PMID 19578367, PMC4501476(freier Volltext).
Margaret Wrensch, Robert B Jenkins, Jeffrey S Chang et al.:Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. In: Nature Genetics. Band41, Nr.8, August 2009, ISSN1061-4036, S.905–908, doi:10.1038/ng.408, PMID 19578366, PMC2923561(freier Volltext).